AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

Background: For estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC), the current standard first-line treatment includes an aromatase inhibitor in combination with a cyclin-dependent kinase 4/6 inhibitor. When resistance occurs, ofte...

Full description

Bibliographic Details
Main Authors: Bardia, A. (Author), Cartot-Cotton, S. (Author), Cohen, P. (Author), Cortes, J. (Author), Delaloge, S. (Author), Hurvitz, S.A (Author), Iwata, H. (Author), Kanagavel, D. (Author), Liu, Q. (Author), O’Shaughnessy, J. (Author), Pelekanou, V. (Author), Shao, Z.-M (Author)
Format: Article
Language:English
Published: SAGE Publications Inc. 2022
Subjects:
amcenestrant
endocrine therapy
ER-positive/HER2-negative
metastatic breast cancer
selective estrogen receptor degrader
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items